Dose-escalation trial of budesonide in surfactant for prevention of bronchopulmonary dysplasia in extremely low gestational age high-risk newborns (SASSIE).

Cindy T McEvoyPhilip L BallardRobert M WardJoseph E RowerRajan WadhawanMark L HudakJoern-Hendrik WeitkampJulia HarrisJeanette AsselinCheryl ChapinRoberta A Ballard

Published in: Pediatric research (2020)

Budesonide/surfactant had no clinical respiratory benefit at any dosing levels for intubated ELGANs. One-tenth the dose used in previous trials had minimal systemic metabolic effects and appeared effective for lung-targeted anti-inflammatory action.

Keyphrases

gestational age
birth weight
preterm birth
anti inflammatory
clinical trial
study protocol
open label
cancer therapy
phase ii
low birth weight
randomized controlled trial
pregnant women
drug delivery
physical activity
weight gain